Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Dose Ranging Study Evaluating Safety, Pharmacokinetics and Clinical Benefit of FLU-IGIV in Hospitalized Patients With Serious Influenza A Infection

NCT03315104 is registered in ClinicalTrials.gov with Emergent BioSolutions as lead sponsor.

NCT NCT03315104
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03315104 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Dose Ranging Study Evaluating Safety, Pharmacokinetics and Clinical Benefit of FLU-IGIV in Hospitalized Patients With Serious Influenza A Infection
Lead sponsor
Emergent BioSolutions
Phase
Phase 2
Overall status
Completed
Start date
November 17, 2017
Completion date
June 17, 2019
Enrollment
65 (actual)
Sites
55

Conditions

As the registry lists them; a condition with its own page is linked.

influenza a h1n1, influenza a h3n2